Recent research has shown that health care consolidations not only lower costs for health care consumers but also improve multiple indicators of quality patient care.
Components of the Inflation Reduction Act have the very real potential of inflating drug prices with arbitrary price controls. Consumers will pay the price.
The proposal to extend the IP waiver under the TRIPS Agreement for COVID-19 diagnostics and therapeutics would worsen the burden on innovators and have disastrous consequences for the American Southwest and the nation.
The deregulation answer to inadequate access
New Mexico is facing a healthcare provider shortage, exacerbated by challenges in medical malpractice payouts and high malpractice caps.
The Medicaid Forward Plan, introduced as House Bill 400, is aimed at creating a state-administered health coverage plan.
We urge the Department of Labor (DOL) to require transparency and disclosure to employers with respect to so-called “shared savings fees” under employer-sponsored health plans to better ascertain their propriety and impact upon millions of Americans.